Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: Implications for regulating the p53·MDM2/MDMX interaction

Journal of Biological Chemistry

Volumn 287, Issue 36, 2012, Pages 30376-30384

  Shan, Bing ^a,b   Li, Da Wei ^a,b   Brüschweiler Li, Lei ^a,b   Brüschweiler, Rafael ^a,b  

^a FLORIDA STATE UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FUNCTIONS; COMPETITIVE BINDING; HYDROPHOBIC POCKETS; MOLECULAR DYNAMICS SIMULATIONS; N-TERMINAL DOMAINS; SITE DIRECTED MUTAGENESIS; SMALL MOLECULE INHIBITOR; SUB-DOMAINS; TRANSACTIVATION; TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVITY; TRANSIENT STRUCTURE;

MOLECULAR DYNAMICS;

NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ARTICLE; BINDING SITE; CONTROLLED STUDY; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION DOMAIN;

HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMIDAZOLES; MUTAGENESIS, SITE-DIRECTED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PIPERAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865798418     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.369793     Document Type: Article

References (60)

1. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307-310
2. Levine, A. J., Hu, W., and Feng, Z. (2006) The P53 pathway. What questions remain to be explored? Cell Death Differ. 13, 1027-1036
3. Joerger, A. C., and Fersht, A. R. (2008) Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582
4. Lambert, P. F., Kashanchi, F., Radonovich, M. F., Shiekhattar, R., and Brady, J. N. (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273, 33048-33053
5. Dumaz, N., and Meek, D. W. (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18, 7002-7010
6. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., and Appella, E. (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275, 9278-9283
7. Schon, O., Friedler, A., Bycroft, M., Freund, S. M., and Fersht, A. R. (2002) Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323, 491-501
8. Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323-331
9. Römer, L., Klein, C., Dehner, A., Kessler, H., and Buchner, J. (2006) p53. A natural cancer killer. Structural insights and therapeutic concepts. Angew. Chem. Int. Ed. Engl. 45, 6440-6460
10. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E., Smith-Sørensen, B., Montesano, R., and Harris, C. C. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555
11. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83
12. Momand, J., Jung, D., Wilczynski, S., and Niland, J. (1998) The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459
13. Marine, J. C., Dyer, M. A., and Jochemsen, A. G. (2007) MDMX. From bench to bedside. J. Cell Sci. 120, 371-378
14. Wade, M., and Wahl, G. M. (2009) Targeting Mdm2 and Mdmx in cancer therapy. Better living through medicinal chemistry? Mol. Cancer Res. 7, 1-11
15. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848
16. Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., and Evan, G. I. (2006)Mdm2is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501-514
17. Marx, J. (2007) Oncology. Recruiting the cell's own guardian for cancer therapy. Science 315, 1211-1213
18. Lee, H., Mok, K. H., Muhandiram, R., Park, K. H., Suk, J. E., Kim, D. H., Chang, J., Sung, Y. C., Choi, K. Y., and Han, K. H. (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 275, 29426-29432
19. Dawson, R., Müller, L., Dehner, A., Klein, C., Kessler, H., and Buchner, J. (2003) The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 332, 1131-1141
20. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953
21. Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., and Holak, T. A. (2007) Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6, 2386-2392
22. Popowicz, G. M., Czarna, A., and Holak, T. A. (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7, 2441-2443
23. Bochkareva, E., Kaustov, L., Ayed, A., Yi, G. S., Lu, Y., Pineda-Lucena, A., Liao, J. C., Okorokov, A. L., Milner, J., Arrowsmith, C. H., and Bochkarev, A. (2005) Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl. Acad. Sci. U.S.A. 102, 15412-15417
24. Teufel, D. P., Freund, S. M., Bycroft, M., and Fersht, A. R. (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc. Natl. Acad. Sci. U.S.A. 104, 7009-7014
25. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245
26. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17, 554-564
27. Chène, P. (2004) Inhibition of the p53-MDM2 interaction. Targeting a protein-protein interface. Mol. Cancer Res. 2, 20-28
28. McCoy, M. A., Gesell, J. J., Senior, M. M., and Wyss, D. F. (2003) Flexible lid to the p53-binding domain of human Mdm2. Implications for p53 regulation. Proc. Natl. Acad. Sci. U.S.A. 100, 1645-1648
29. Showalter, S. A., Bruschweiler-Li, L., Johnson, E., Zhang, F., and Brüschweiler, R. (2008) Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J. Am. Chem. Soc. 130, 6472-6478
30. Zhu, J., Zhou, W., Jiang, J., and Chen, X. (1998) Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273, 13030-13036
31. Chi, S. W., Lee, S. H., Kim, D. H., Ahn, M. J., Kim, J. S., Woo, J. Y., Torizawa, T., Kainosho, M., and Han, K. H. (2005) Structural details on mdm2- p53 interaction. J. Biol. Chem. 280, 38795-38802
32. Kallen, J., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., and Lisztwan, J. (2009) Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational changes. J. Biol. Chem. 284, 8812-8821
33. Sanchez, M. C., Renshaw, J. G., Davies, G., Barlow, P. N., and Vogtherr, M. (2010)MDM4binds ligands via a mechanism in which disordered regions become structured. FEBS Lett. 584, 3035-3041
34. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe. A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293
35. Johnson, B. A. (2004) Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol. Biol. 278, 313-352
36. Marsh, J. A., Singh, V. K., Jia, Z., and Forman-Kay, J. D. (2006) Sensitivity of secondary structure propensities to sequence differences between α-and γ-synuclein. Implications for fibrillation. Protein Sci. 15, 2795-2804
37. Hess, B., Kutzner, C., van der Spoel, D., and Lindahl, E. (2008) GROMACS 4. Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435-447
38. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725
39. Li, D. W., and Brüschweiler, R. (2011) Iterative Optimization of molecular mechanics force fields from NMR data of full-length proteins. J. Chem. Theory Comput. 7, 1773-1782
40. Fields, S., and Jang, S. K. (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249, 1046-1049
41. Di Lello, P., Jenkins, L. M., Jones, T. N., Nguyen, B. D., Hara, T., Yamaguchi, H., Dikeakos, J. D., Appella, E., Legault, P., and Omichinski, J. G. (2006) Structure of the Tfb1/p53 complex. Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell 22, 731-740
42. Lee, C. W., Martinez-Yamout, M. A., Dyson, H. J., and Wright, P. E. (2010) Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry 49, 9964-9971
43. Wells, M., Tidow, H., Rutherford, T. J., Markwick, P., Jensen, M. R., Mylonas, E., Svergun, D. I., Blackledge, M., and Fersht, A. R. (2008) Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc. Natl. Acad. Sci. U.S.A. 105, 5762-5767
44. Uhrinova, S., Uhrin, D., Powers, H., Watt, K., Zheleva, D., Fischer, P., McInnes, C., and Barlow, P. N. (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53 binding. J. Mol. Biol. 350, 587-598
45. Tang, C., Iwahara, J., and Clore, G. M. (2006) Visualization of transient encounter complexes in protein-protein association. Nature 444, 383-386
46. Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., and Marine, J. C. (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 3232-3237
47. Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., and Lozano, G. (2006) Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. U.S.A. 103, 3226-3231
48. Khoury, K., Grzegorz M. Popowicz, Holak, T. A., and Domling, A. (2011) The p53-MDM2/MDMX axis.Achemotype perspective. Medchemcomm 2, 246-260
49. Hu, B., Gilkes, D. M., and Chen, J. (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res. 67, 8810-8817
50. Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., and Lu, W. (2009) Structural basis for high affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl. Acad. Sci. U.S.A. 106, 4665-4670
51. Li, C., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W. Y., and Lu, W. (2010) Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J. Mol. Biol. 398, 200-213
52. Dyson, H. J., and Wright, P. E. (2002) Coupling of folding and binding for unstructured proteins. Curr. Opin. Struct. Biol. 12, 54-60
53. Mohan, A., Oldfield, C. J., Radivojac, P., Vacic, V., Cortese, M. S., Dunker, A. K., and Uversky, V. N. (2006) Analysis of molecular recognition features (MoRFs). J. Mol. Biol. 362, 1043-1059
54. Dyson, H. J., and Wright, P. E. (2005) Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6, 197-208
55. Demarest, S. J., Deechongkit, S., Dyson, H. J., Evans, R. M., and Wright, P. E. (2004) Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB-binding protein. Protein Sci. 13, 203-210
56. De Guzman, R. N., Martinez-Yamout, M. A., Dyson, H. J., and Wright, P. E. (2004) Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of CITED2. Regulation by competition between intrinsically unstructured ligands for non-identical binding sites. J. Biol. Chem. 279, 3042-3049
57. Sugase, K., Dyson, H. J., and Wright, P. E. (2007) Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 447, 1021-1025
58. Pawson, T. (1995) Protein modules and signaling networks. Nature 373, 573-580
59. Baker, J. M., Hudson, R. P., Kanelis, V., Choy, W. Y., Thibodeau, P. H., Thomas, P. J., and Forman-Kay, J. D. (2007) CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat. Struct. Mol. Biol. 14, 738-745
60. Mittag, T., Orlicky, S., Choy, W. Y., Tang, X., Lin, H., Sicheri, F., Kay, L. E., Tyers, M., and Forman-Kay, J. D. (2008) Dynamic equilibrium engagement of a polyvalent ligand with a single-site receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 17772-17777